National Cancer Institute; Notice of Closed Meetings, 19674 [2012-7824]
Download as PDF
<![CDATA[
19674
Federal Register / Vol. 77, No. 63 / Monday, April 2, 2012 / Notices
accomplishing reinvention goals is the
ability to periodically receive input and
feedback from customers about the
design and quality of the services they
receive.
The NLM provides significant
services directly to the public including
health providers, researchers,
universities, other federal agencies, state
and local governments, and to others
through a range of mechanisms,
including publications, technical
assistance, and Web sites. These
services are primarily focused on health
and medical information dissemination
activities. The purpose of this
submission is to obtain OMB’s generic
approval to continue to conduct
satisfaction surveys of NLM’s
customers. The NLM will use the
information provided by individuals
and institutions to identify strengths
and weaknesses in current services and
to make improvements where feasible.
The ability to periodically survey NLM’s
customers is essential to continually
Estimated
number of
respondents
Types of respondents
Researchers, Physicians, Other Health Care Providers, Librarians, Students, General Public ...................................................................................
The annualized cost to respondents
for each year of the generic clearance is
estimated to be $20,670. There are no
Capital Costs, Operating Costs, and/or
Maintenance Costs to report.
Request for Comments: Written
comments and/or suggestions from the
public and affected agencies should
address one or more of the following
points: (1) Evaluate whether the
proposed collection of information is
necessary for the proper performance of
the function of the agency, including
whether the information will have
practical utility; (2) Evaluate the
accuracy of the agency’s estimate of the
burden of the proposed collection of
information, including the validity of
the methodology and assumptions used;
(3) Enhance the quality, utility, and
clarity of the information to be
collected; and (4) Minimize the burden
of the collection of information on those
who are to respond, including the use
of appropriate automated, electronic,
mechanical, or other technological
collection techniques or other forms of
information technology.
To
request more information on the
proposed project or to obtain a copy of
the data collection plans and
instruments, contact: David Sharlip,
National Library of Medicine, Building
38A, Room B2N12, 8600 Rockville Pike,
Bethesda, MD 20894, or call non-toll
free number 301–402–9680 or Email
your request to sharlipd@mail.nih.gov.
Comments Due Date: Comments
regarding this information collection are
best assured of having their full effect if
received within 60 days of the date of
this publication.
mstockstill on DSK4VPTVN1PROD with NOTICES
FOR FURTHER INFORMATION CONTACT:
VerDate Mar<15>2010
17:42 Mar 30, 2012
Jkt 226001
[FR Doc. 2012–7831 Filed 3–30–12; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Cancer
Institute Special Emphasis Panel; Small
Grants for Behavioral Research in Cancer
Control (R03).
Date: June 7, 2012.
Time: 8:30 a.m. to 4 p.m.
Agenda: To review and evaluate grant
applications.
Place: Doubletree Hotel Bethesda, 8120
Wisconsin Avenue, Bethesda, MD 20814.
Contact Person: Ellen K Schwartz, EDD,
MBA, Scientific Review Officer,Special
Review & Logistics Branch, Division of
Extramural Activities, National Cancer
Frm 00065
Fmt 4703
Sfmt 9990
Estimated
number of
responses per
respondent
15,000
Dated: March 27, 2012.
David H. Sharlip,
NLM Project Clearance Liaison, National
Library of Medicine, National Institutes of
Health.
PO 00000
update and upgrade methods of
providing high quality service.
Frequency of Response: Annually or
biennially. Affected Public: Individuals
or households; businesses or other for
profit; state or local governments;
Federal agencies; non-profit institutions;
small businesses or organizations. Type
of Respondents: Organizations, medical
researchers, physicians and other health
care providers, librarians, students, and
the general public. The annual reporting
burden is as follows:
Average
burden hours
per response
1
Estimated total
annual burden
hours
requested
.150
2,250
Institute, NIH, 6116 Executive Boulevard
Room 8055B, Bethesda, MD 20892–8329,
301–594–1215, schwarel@mail.nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel; Innovative
Molecular Analysis Technologies for Cancer
(R21).
Date: June 26–27, 2012.
Time: 8 a.m. to 6 p.m.
Agenda: To review and evaluate grant
applications and/or proposals.
Place: Doubletree Hotel Bethesda, 8120
Wisconsin Avenue, Bethesda, MD 20814.
Contact Person: Jeffrey E. DeClue, Ph.D.,
Scientific Review Officer, Special Review
and Logistics Branch, Division of Extramural
Activities, National Cancer Institute, NIH,
6116 Executive Boulevard Room 8059,
Bethesda, MD 20892–8329, 301–496–7904,
decluej@mail.nih.gov.
Information is also available on the
Institute’s/Center’s home page: https://
deainfo.nci.nih.gov/advisory/sep/sep.htm,
where an agenda and any additional
information for the meeting will be posted
when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
Dated: March 27, 2012.
Jennifer S. Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 2012–7824 Filed 3–30–12; 8:45 am]
BILLING CODE 4140–01–P
E:\FR\FM\02APN1.SGM
02APN1
]]>Agencies
[Federal Register Volume 77, Number 63 (Monday, April 2, 2012)]
[Notices]
[Page 19674]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-7824]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of the following
meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Cancer Institute Special Emphasis
Panel; Small Grants for Behavioral Research in Cancer Control (R03).
Date: June 7, 2012.
Time: 8:30 a.m. to 4 p.m.
Agenda: To review and evaluate grant applications.
Place: Doubletree Hotel Bethesda, 8120 Wisconsin Avenue,
Bethesda, MD 20814.
Contact Person: Ellen K Schwartz, EDD, MBA, Scientific Review
Officer,Special Review & Logistics Branch, Division of Extramural
Activities, National Cancer Institute, NIH, 6116 Executive Boulevard
Room 8055B, Bethesda, MD 20892-8329, 301-594-1215,
schwarel@mail.nih.gov.
Name of Committee: National Cancer Institute Special Emphasis
Panel; Innovative Molecular Analysis Technologies for Cancer (R21).
Date: June 26-27, 2012.
Time: 8 a.m. to 6 p.m.
Agenda: To review and evaluate grant applications and/or
proposals.
Place: Doubletree Hotel Bethesda, 8120 Wisconsin Avenue,
Bethesda, MD 20814.
Contact Person: Jeffrey E. DeClue, Ph.D., Scientific Review
Officer, Special Review and Logistics Branch, Division of Extramural
Activities, National Cancer Institute, NIH, 6116 Executive Boulevard
Room 8059, Bethesda, MD 20892-8329, 301-496-7904,
decluej@mail.nih.gov.
Information is also available on the Institute's/Center's home
page: https://deainfo.nci.nih.gov/advisory/sep/sep.htm, where an
agenda and any additional information for the meeting will be posted
when available.
(Catalogue of Federal Domestic Assistance Program Nos. 93.392,
Cancer Construction; 93.393, Cancer Cause and Prevention Research;
93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer
Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer
Control, National Institutes of Health, HHS)
Dated: March 27, 2012.
Jennifer S. Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 2012-7824 Filed 3-30-12; 8:45 am]
BILLING CODE 4140-01-P
